United States: FDA Issues Two Draft Guidance Documents Relating To Internet And Social Media Use By Drug And Device Manufacturers

On June 17, 2014, the Food and Drug Administration ("FDA") released two draft guidance documents related to manufacturer communications on the Internet and social media platforms. The two documents are (1) "Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices" (Draft Guidance on Correcting Misinformation); and (2) "Internet/Social Media Platforms with Character Space Limitations – Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices" (Draft Guidance on Character Space Limitations).

The Draft Guidance on Correcting Misinformation indicates as a threshold matter that drug and device manufacturers have no obligation to correct misinformation about their products provided on the Internet or social media by an independent third party and also addresses how manufacturers should correct misinformation if they so choose. The Draft Guidance on Character Space Limitations provides FDA's recommendations for drug and device product promotion on electronic platforms with character space limitations, such as Twitter, which limits messages to 140 character spaces, and sponsored links, which have their own character space limitations and other constraints depending on the platform. This alert summarizes the key aspects of each document.

Draft Guidance for Correcting Third-Party Misinformation Communicated on Internet and Social Media Platforms

The Draft Guidance on Correcting Misinformation provides recommendations for companies that wish to correct misinformation about their prescription drugs and medical devices posted by independent parties on the Internet or through social media and indicates that so long as the correction occurs in a manner consistent with the recommendations, FDA will not expect it to comply with otherwise applicable advertising and labeling requirements (e.g., comparable presentation of benefits and risks).

Fundamental Principles. The Draft Guidance on Correcting Misinformation applies only to misinformation for which a drug or device manufacturer is not responsible. When content is "owned, controlled, created, [] influenced, or affirmatively adopted or endorsed by, or on behalf of, the firm," the firm is obligated to correct the misinformation, and those corrective communications are subject to regulatory requirements for advertising and labeling. By contrast, when content is "truly independent" of the company (e.g., found on a third-party site that is "not produced by, or on behalf of, or prompted by the firm in any particular"), the company may attempt to correct the misinformation but is not required to do so.

Appropriate Corrective Information. If a company decides voluntarily to correct misinformation on a third-party site, FDA recommends that the communication disclose the affiliation of the person providing the information and be:

  • Relevant and responsive to the misinformation;
  • Limited and tailored to the misinformation;
  • Non-promotional in nature, tone, and presentation;
  • Accurate;
  • Consistent with FDA-required labeling for the product;
  • Supported by sufficient evidence; and
  • Posted in conjunction with the misinformation.

Scope of the Correction. The Draft Guidance on Correcting Misinformation clarifies that if a company corrects one piece of information on a site, such as a single comment to a news article, it is not obligated to correct each piece of information in the entire forum; moreover, FDA does not expect companies to continually monitor and correct misinformation on an ongoing basis. The Draft Guidance on Correcting Misinformation does indicate, however, that companies should not "cherry pick" the misinformation to correct (e.g., by correcting information that overstates a product's risks but allowing information that overstates the benefits to remain).

How to Correct Misinformation. Companies may attempt to remedy misinformation by:

  • Correcting misinformation directly on the site;
  • Providing the corrective information to the independent author for incorporation;
  • Requesting that the author or site administrator remove the misinformation or allow corrective comments to be posted.

When correcting misinformation, the Draft Guidance recommends that companies clearly define the portion that is corrected, provide the correction date, and keep records related to the content of the information, where it appeared, and how it was corrected. Additionally, the Draft Guidance on Correcting Misinformation explains that the correction should be tailored specifically to address the information that was incorrect; if, for example, a company submitted corrective information regarding a contraindication but also provided comparative safety information to a competitor's product unrelated to the contraindication, the communication would fall outside the scope of the Draft Guidance on Correcting Misinformation.

Implications for Industry. The Draft Guidance on Correcting Misinformation provides drug and device manufacturers with significant discretion to determine when to correct misinformation posted on the Internet or social media by a third party. Importantly, the agency has clarified that companies are not obligated to correct such misinformation and that even if they choose to do so, a decision to correct a single incorrect user comment does not translate into an obligation to comb through an entire site in search of all instances of misinformation or the obligation to monitor the site on an ongoing basis. As with FDA's January 2014 Draft Guidance on Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media, however, the Draft Guidance on Correcting Misinformation advances a broad interpretation of when a company may be responsible for content on the web or social media, and more elaboration is needed to determine what communications may be viewed by the agency as "truly independent" of a manufacturer and thereby covered by the Draft Guidance.

Draft Guidance for Promotional Material on Platforms with Character Space Limitations

The Draft Guidance on Character Space Limitations provides recommendations for drug and device companies that promote their products on platforms with character space limitations. At bottom, the Draft Guidance on Character Space Limitations makes clear that FDA expects product messaging to comply with all applicable regulations related to advertising and labeling—regardless of the constraints associated with the social media platform—and indicates that Twitter and similar forms of media may not be appropriate for promotion of products with complex indications or serious risks.

Presenting Benefit Information

The Draft Guidance on Character Space Limitations provides three recommendations for the communication of benefit information:

  • Benefit information should be accurate and non-misleading and should reveal material facts, such as limitations to an indication or the relevant patient population, within each individual message or tweet.
  • Benefit information should be accompanied by risk information within each individual message or tweet.
  • If a firm concludes that adequate benefit and risk information, as well as other required information, cannot be communicated within the same message or tweet, the firm should reconsider using that platform for the intended promotional message.

Presenting Risk Information

FDA recommends that communication of risk information adhere to the following principles:

  • Risk information should be presented together with benefit information in the same message or tweet.
  • The content of risk information should, at a minimum, include the most serious risks associated with the product. For prescription drugs, FDA expects a message to include all risk concepts from a boxed warning, all risks that are known to be fatal or life-threatening, and all contraindications from the approved product labeling; if a product does not have a boxed warning and is not associated with fatal or life-threatening risks or any contraindications, FDA recommends that companies communicate "the most significant warnings or precautions about the product." For devices, the agency recommends that the message include information about each risk associated with a particular identifiable use or population.
  • A hyperlink should be provided to allow direct access to a more complete discussion of risk information. The Draft Guidance on Character Space Limitations recommends that companies include a direct link to a landing page exclusively devoted to the communication of risk information about the product; the link may not, in other words, direct users to the PI or a product's promotional home page.
  • The prominence of risk information should be comparable to the benefit information, taking into account any formatting capabilities available on the specific platform. FDA recommends that companies use similar techniques to emphasize both benefit information and risk information for the product. Additionally, the guidance recommends that companies utilize any formatting capabilities (e.g., bolded text) to highlight significant risk information.

Presenting Other Product Information

In addition to benefit and risk information, the Draft Guidance on Character Space Limitations recommends that:

  • Companies include both the proprietary name and the established (i.e., generic) name of the product in a single message or tweet; and
  • For prescription drugs, quantitative ingredient information and at least one dosage form should be prominently displayed on the landing page.

Implications for FDA Regulation of Platforms with Character Space Limitations

While the Draft Guidance on Character Space Limitations does provide some clarity on how FDA intends to regulate promotional messaging on space-limited platforms, it is fairly limited in scope and does not cover promotion via other types of social media such as product pages on Facebook and YouTube, Twitter profiles, and online web banners. As a practical matter, it may be difficult to craft tweets and similar messages for many drugs and devices because 140 characters may not be sufficient to include the established and proprietary names, product benefits, detailed risk information, and hyperlink to a separate page devoted to product safety information. That said, the Draft Guidance on Character Space Limitations does provide a clear path forward for the promotion of low-risk drugs and devices with benefit and risk information that can be succinctly communicated, and it permits companies to use space-limited platforms in other ways, such as for reminder advertisements, disease-awareness communications, and other messaging.

FDA will be accepting comments on both drafts until September 16, 2014.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions